医学
抗原
干细胞
嵌合抗原受体
抗原提呈细胞
癌症研究
癌症干细胞
癌症
免疫学
免疫系统
细胞生物学
免疫疗法
生物
T细胞
内科学
作者
Andreas A. Hombach,Hinrich Abken
标识
DOI:10.1080/1744666x.2016.1221763
摘要
Introduction: Adoptive therapy with chimeric antigen receptor (CAR) T cells redirected towards CD19 produces remissions of B cell malignancies, however, it also eradicates healthy B cells sharing the target antigen. Such ‘on-target off-tumor’ toxicity raises serious safety concerns when the target antigen is also expressed by tissue stem cells, with the risk of lasting tissue destruction.Areas covered: We discuss CAR T cell targeting of activation antigens versus lineage associated antigens on the basis of recent experimental and animal data and the literature in the field.Expert commentary: Targeting an activation associated antigen which is transiently expressed by stem cells seems to be safe, like CAR T cells targeting CD30 spare CD30+ hematopoietic stem and progenitor cells while eliminating CD30+ lymphoma cells, whereas targeting lineage associated antigens which increase in expression during cell maturation, like folate receptor-β and CD123, is of risk to destruct tissue stem cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI